Opposition to Myriad Genetics patents and their total or partial revocation in Europe: Early conclusions;L'opposition contre les brevets de Myriad Genetics et leur révocation totale ou partielle en Europe: Premiers enseignement

Medecine/Sciences

Volumn 21, Issue 6-7, 2005, Pages 658-662

  Cassier, Maurice ^a   Stoppa Lyonnet, Dominique ^b  

^a INSERM   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; EUROPE; FRANCE; GENBANK; GENE SEQUENCE; GENETIC ANALYSIS; GENETICS; MEDICAL SERVICE; ONCOGENE; PATENT; PUBLIC HEALTH; REVIEW;

EID: 22144495432     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2005216-7658     Document Type: Review

References (7)

1. Phélip B. Le point de vue juridique. In: Académie des Sciences-Actes de colloques. La propriété intellectuelle dans le domaine du vivant. Paris: Académie des Sciences, 1995: 97-106.
2. Cassier M. Relations entre secteur public et privé dans la recherche sur le génome. Med Sci (Paris) 2000; 16: 26-30.
3. Wadman M. Testing time for gene patents as Europe rebels. Nature 2001; 413: 443.
4. Gad S, Scheuner MT, Pages-Berhouet S, et al. Identification of a large rearrangement of the BRCA1 gene using color bar code on combed DNA in an americana breast/ovarian cancer family previously studied by direct sequencing. J Med Genet 2001; 38: 388-91.
5. Abbott A. Clinicians win fight to overturn patent for breast-cancer gene. Nature 2004; 429: 329.
6. Sevilla C, Bourret P, Noguès C, et al. L'offre de tests de prédisposition génétique au cancer du sein ou de l'ovaire en France. Med Sci (Paris) 2004; 20: 788-92.
7. The ethics of patenting DNA. London: Nuffield Council on Bioethics, 2002: 94 p.